Claims
- 1. A composition comprising an apo-carbonic anhydrase protein and a photoluminescent molecule selected from the group consisting of dansyl aziridine, 4-chloro-7-sulfobenzofurazan, 7-fluorobenz-2-oxa-1,3-diazole-4-sulfonamide and 4-nitrobenzoxadiazol-7-chloride, or a composition comprising the reaction product of an apo-carbonic anhydrase protein and a photoluminescent molecule selected from the group consisting of dansyl aziridine, 4-chloro-7-sulfobenzofurazan, 7-fluorobenz-2-oxa-1,3-diazole-4-sulfonamide and 4-nitrobenzoxadiazol-7-chloride.
- 2. A composition comprising an apo-carbonic anhydrase protein and a photoluminsecent molecule selected from the group consisting of 7-fluorobenz-2-oxa-1,3-diazole-4-sulfonamide: β-mercaptoethanol adduct, dansylamide, hydroxynaphthalenesulphonamide, 2-(3-methoxy-4-ethoxyphenyl)-4-chloroquinoline-6-sulfonamide, N-(1-anthracenyl)-4-sulfonamido-benzenesulfonamide, ethyl-2-(4-sulfonamidophenyl)-4-hydroxyquinoline-6-carboxylate and N-(N′-(4′-sulfamoylglutaranily-amidoethyl))-4-amino-3,6-disulfo-1,8-naphthalimide.
- 3. The composition of claim 1, wherein the photoluminescent molecule is conjugated to the apo-carbonic anhydrase protein.
- 4. The composition of claim 1, wherein the apo-carbonic anhydrase protein is a human apo-carbonic anhydrase.
- 5. The composition of claim 2, wherein the apo-carbonic anhydrase protein is a human apo-carbonic anhydrase.
- 6. The composition of claim 1, wherein the apo-carbonic anhydrase protein is a human carbonic anhydrase II isozyme or a variant thereof having a cysteine replacement of one amino acid.
- 7. The composition of claim 1, wherein the apo-carbonic anhydrase is one selected from the group consisting of carbonic anhydrase II (L198C), carbonic anhydrase II (V143C), carbonic anhydrase II (H64C).
- 8. The composition of claim 5, wherein the photoluminescent molecule is conjugated to the apo-carbonic anhydrase through the cysteine replacement amino acid.
- 9. The composition of claim 6, wherein the photoluminescent molecule is conjugated to the apo-carbonic anhydrase through the cysteine replacement amino acid.
- 10. The composition of claim 7, wherein carbonic anhydrase II (V143C) is conjugated to dansyl aziridine.
- 11. The composition of claim 7, wherein carbonic anhydrase II (L198C) is conjugated to 4-chloro-7-sulfobenzofurazan.
- 12. The composition of claim 7, wherein carbonic anhydrase II (H64C) is conjugated to 7-flurobenz-2-oxa-1,3-diazole-4-sulfonamide.
- 13. The composition of claim 2, wherein the photoluminescent molecule is 7-fluorobenz-2-oxa-1,3-diazole-4-sulfonamide: β-mercaptoethanol adduct.
- 14. A kit for assay of divalent metal ion concentration in a sample comprising:
i) an apo-carbonic anhydrase protein conjugated to a photoluminescent molecule selected from the group consisting of dansyl aziridine, 4-chloro-7-sulfobenzofuran, 7-flurorbenz-2-oxa-1,3-diazole-4-sulfonamide and nitrobenzoxadiazolyl; ii) optionally a standard solution of at least one divalent metal ion; iii) optionally a buffer for maintaining a concentration of free divalent metal ions in a solution; and iv) optionally a chelating resin to prevent or remove unwanted metal contamination; said items i), ii), iii) and iv) being packaged in a container that prevents unwanted contamination by divalent metal ions.
- 15. The kit of claim 13, wherein the buffer for maintaining a concentration of free divalent metal ions is nitrilotriacetic acid.
- 16. The kit of claim 13, wherein item ii) is included.
- 17. The kit of claim 13, wherein item iii) is included.
- 18. The kit of claim 13, wherein item iv) is included.
- 19. The kit of claim 13, wherein items ii) and iii) are included.
- 20. The kit of claim 13, wherein items ii) and iv) are included.
- 21. The kit of claim 13, wherein items ii), iii) and iv) are included.
- 22. The kit of claim 13, wherein items iii) and iv) are included.
- 23. A kit for assay of divalent metal ion concentration in a sample comprising:
i) an apo-carbonic anhydrase protein; ii) a photoluminsecent molecule selected from the group consisting of 4-aminosulfonyl[1-(4-N-(5-fluoresceinylthioureido)butyl]benzamide, 7-flurorbenz-2-oxa-1,3-diazole-4-sulfonamide: p-mercaptoethanol adduct, dansylamide, hydroxynaphthalenesulphonamide, 2- (3-methoxy-4-ethoxyphenyl)-4-chloroquinoline-6-sulfonamide, N-(1-anthracenyl)-4-sulfonamido-benzenesulfonamide, ethyl-2-(4-sulfonamidophenyl)-4-hydroxyquinoline-6-carboxylate and N-(N′-(4′-sulfamoylglutaranily-amidoethyl))-4-amino-3,6-disulfo-1,8-naphthalimide iii) optionally a standard solution of a divalent metal ion; iv) optionally a buffer for maintaining a concentration of free divalent metal ion in a solution; and v) optionally a chelating resin to prevent or remove unwanted metal contamination; said items i), ii), iii), iv) and v) being packaged in a container that prevents unwanted contamination by divalent metal ions.
- 24. The kit of claim 22, wherein the buffer for maintaining a concentration of free divalent metal ion is nitrilotriacetic acid or MOPS.
CROSS-REFERENCE TO A RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/045,289, filed May 1, 1997, the contents of which are incorporated herein.
Statement as to Rights to Inventions Made Under Federally Sponsored Research and Development
[0002] This invention was made with the support of the U.S. Government under Grant Nos. N00014-91-1572 and BES-9613556 awarded by the Office of Naval Research and the National Science Foundation, respectively. The Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60045289 |
May 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09071351 |
Apr 1998 |
US |
Child |
09942708 |
Aug 2001 |
US |